The 2 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 4.75, with a high estimate of 5.00 and a low estimate of 4.50. The median estimate represents a +135.15% increase from the last price of 2.02.
The current consensus among 2 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.08
Reporting Date Aug 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.